Literature DB >> 28329582

Cyclosporine in toxic epidermal necrolysis: a brief review of the emerging therapeutic modality.

Piyush Kumar1, Nilay Kanti Das.   

Abstract

Toxic epidermal necrolysis (TEN) is a severe life-threatening adverse drug reaction that predominantly involve the skin and mucous membranes, and is associated with high mortality (25-35% or even higher) and with various long term sequelae. There is no universally accepted treatment for TEN, but key elements of management include rapid diagnosis, identification and interruption of the culprit drug, evaluation of the prognosis using SCORTEN, specialized supportive care ideally in an intensive care unit, and consideration of immunomodulating agents. Cyclosporine has recently emerged as a promising immunomodulating agent in the management of TEN and we have performed a brief review of evidence highlighting its role in TEN management.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28329582

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  4 in total

Review 1.  Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Akito Hasegawa; Riichiro Abe
Journal:  F1000Res       Date:  2020-06-16

Review 2.  A contemporary snippet on clinical presentation and management of toxic epidermal necrolysis.

Authors:  Piyu Parth Naik
Journal:  Scars Burn Heal       Date:  2022-09-13

Review 3.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.

Authors:  Jeremy A Schneider; Philip R Cohen
Journal:  Adv Ther       Date:  2017-04-24       Impact factor: 3.845

4.  A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis.

Authors:  Qin Xiang Ng; Michelle Lee Zhi Qing De Deyn; Nandini Venkatanarayanan; Collin Yih Xian Ho; Wee-Song Yeo
Journal:  J Inflamm Res       Date:  2018-03-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.